Biosense Webster Showcases Commitment to Patient-centered Innovation at Heart Rhythm 2022

Biosense Webster logo for Heart Rhythm 2022

Presentations include data highlighting the role of diagnostic and therapeutic catheters, mapping software and digital technologies in advancing cardiac arrhythmia treatment, and real-world evidence informing treatment pathways and patient care 

On-site booth will host interactive experiences including product trials, hands-on demonstrations, and education

San Francisco, CA – April 28, 2022 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech*, announced today that data from 23 company-sponsored and funded studies will be presented at Heart Rhythm 2022, the Heart Rhythm Society's annual meeting, taking place in San Francisco April 29– May 1. The data presented reflects Biosense Webster’s continued innovation and commitment to advancing science in the field of electrophysiology with the goal of improving the lives of patients. Presentation topics include new data on diagnostic and therapeutic catheters, the role of digital technologies in advancing cardiac arrhythmia treatment, and real-world evidence investigating the impact of catheter ablation on patient outcomes.  

“At Biosense Webster, our mission is to ‘discover a new possible’ to help those with cardiac arrhythmias live the lives they want,” said Michael Bodner, Ph.D., Worldwide President, Biosense Webster, Inc. “At Heart Rhythm 2022, we will showcase how we are living into this mission by leading the way in innovation, our service, partnerships, and our work to increase access to AFib care. We are excited to meet with our customers and partners at our interactive booth, highlight data from studies supported by our company, and invite physicians to experience our latest technology as we work together to advance the future of AFib treatment for patients around the world.”

Interactive In-Booth Experiences 
As part of the Biosense Webster booth, a variety of interactive experiences will be available including hands-on demonstrations of the new OCTARAY™ Mapping Catheter with TRUEref™ Technology, the recently 510(k) cleared OPTRELL™ Mapping Catheter, and the NUVISION™ Ultrasound Catheter with imaging support from GE Healthcare Vivid™ Ultra Edition ultrasound systems.  

A Commitment to Advancing Scientific Research 
Data from 23 Biosense Webster-sponsored and funded studies will be presented, spanning key topics in electrophysiology. Highlights of the data being presented include:

Therapeutic Catheters and Technology

  • Late-breaking oral presentation Clinical and Economic Impact Of An Organized Treatment Pathway On Atrial Fibrillation Patient From The Emergency Room To Electrophysiology Service (ER2EP Study) Session LB-735 / Room 24. Presented April 29, 10:45 am – 10:57 am By Dr. Dhanunjaya Lakkireddy
  • Tailored Ablation Index Based On Left Atrial Wall Thickness Assessed By Computed Tomography For Pulmonary Vein Isolation In Patients With Atrial Fibrillation. Oral Presentation Session CA-530-03 / Room 207. Presented April 29, 2:45 pm – 3:00 pm By Drs. So-Ryoung Lee and Eue-Keun Choi

Diagnostic and Mapping Technology

  • Multipolar Electrograms: A Novel Algorithm For Accurate Annotation Of Near-Field Potentials In Scar. Poster Session PO-617-01 / Abstract Pavilion Pod 4. Presented April 29, 12:30 pm – 12:45 pm By Dr. Arwa Younis
  • Prospective Evaluation Of The Wave Dynamics Using High Density Vector Field Mapping For Persistent Atrial Fibrillation To Detect The Arrhythmogenic Sources. Oral Presentation Session CA-529-02 / Room 205. Presented April 29, 1:15 pm – 1:30 pm By Dr. Yenn-Jiang Lin
  • Characterisation of Fascicular Activation In The Post-Infarct Ventricle Using Ripple Mapping. Poster Session PO-684-03 / Abstract Pavilion Pod 11. Presented April 30, 3:30 pm – 3:45 pm By Drs. George Katritsis and Prapa Kanagaratnam
  • The Clinical Value And Long-term Outcome Of Catheter Ablation By Using High Density Vector Field Mapping For Persistent Atrial Fibrillation. Poster Session PO-681-04 / Abstract Pavilion Pod 08. Presented April 30, 3:45 pm – 4:00 pm By Drs. Ming-Jen Kuo and Chia-Hsin Chiang
  • Real-World Experience With A Novel 3D Intracardiac Echocardiography Catheter. Poster Session PO-696-06 / Abstract Pavilion Pod 08. Presented May 1, 10:45 am – 11:00 am By Dr. Domenico Della Rocca

Digital Technology 

  • Lesion Quality And Safety Maintained As Trainees Develop Catheter Handling Skills And Progress To Independence: Cloud-Based Analysis. Oral Presentation Session HP-573-01 / Room 022 Presented April 30, 9:15 am – 9:30 am By Dr. John Whitaker
  • The Association Between Intraprocedural Impedance Drop And Atrial Fibrillation Ablation Success Using CARTO Data Linked to Electronic Health Record Data. Poster Session PO-661-04 / Abstract Pavilion Pod 03. Presented April 30, 1:15 pm – 1:30 pm By Drs. Rahul Khanna and Amit Doshi

Real-World AFib Outcomes 

  • Use Of Healthcare Data Collected By Apple Watch To Predict Atrial Fibrillation Attacks. Oral Presentation Session DH-576-01 / Room 011. Presented April 29, 10:30 am – 10:45 am By Dr. Takehiro Kimura
  • Rates And Predictors Of Hospital And Emergency Department Care After Catheter Ablation Of Atrial Fibrillation. Poster Session PO-634-05/ Abstract Pavilion Pod 06. Presented April 29, 4:00 pm – 4:15 pm By Dr. Daniel Friedman
  • Risk Of Dementia Among Patients With Atrial Fibrillation Treated With Catheter Ablation Versus Anti-arrhythmic Drugs. Oral Presentation Session CA-532-01 / Room 307. Presented April 30, 8:00 am – 8:15 am By Dr. Emily Zeitler

Data from REAL-AF Registry (NCT04088071)

  • Clinical And Procedural Predictors Of First Pass Pulmonary Vein Isolation- Findings From The Analysis Of 1539 First Time Atrial Fibrillation Ablations In The REAL-AF Registry. Poster Session PO-636-05 / Abstract Pavilion Pod 08. Presented April 29, 4:00 pm – 4:15 pm By Dr. Omar Kreidieh 
  • Same Day Discharge After Catheter Ablation Of Atrial Fibrillation In A Multicenter Registry (REAL-AF). Poster Session PO-667-01 / Abstract Pavilion Pod 09. Presented April 30, 12:30 pm – 12:45 pm By Dr. Anil Rajendra
  • Radiofrequency Ablation Of Paroxysmal Atrial Fibrillation In Octogenarians: Insights From A Multicenter Registry (REAL-AF). Poster Session PO-667-03 / Abstract Pavilion Pod 09. Presented April 30, 1:00 pm – 1:15 pm By Dr. Anil Rajendra
  • Engagement In A Digital Registry-based Learning Collaborative: Preliminary Findings And Lessons Learned. Poster Session PO-659-06 / Abstract Pavilion Pod 01. Presented April 30, 1:45 – 2:00 pm By Dr. Allyson Varley
  • Association Of Body Mass Index With Clinical And Procedural Characteristics in Patients Undergoing Catheter Ablation For Paroxysmal Atrial Fibrillation. Poster Session PO-697-01 / Abstract Pavilion Pod 09. Presented May 1, 9:30 am – 9:45 am By Dr. Sandeep Goyal

For more information about Biosense Webster’s presence at Heart Rhythm 2022, visit

Media Contacts: 
Diane Pressman
Email: [email protected]

Charlene DeBar
Email: [email protected]

About Biosense Webster
Biosense Webster is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of the Johnson & Johnson Family of Companies, the specialized medical-technology company is headquartered in Irvine, Calif., and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. Learn more at and connect on LinkedIn and Twitter.

About Johnson & Johnson Medical Devices Companies 
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Cautions Concerning Forward-Looking Statements 
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding NUVISION™ Ultrasound Catheter. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc., any of the other Johnson & Johnson MedTech Companies and/or Johnson & Johnson. Risks and uncertainties include but are not limited to uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Neither Biosense Webster, Inc., the Johnson & Johnson MedTech Companies, nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson MedTech comprises the surgery, orthopedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment. 

© Biosense Webster, Inc. 2022 208455-220401